The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sidorov D.V.

City Clinical Oncology Hospital One Moscow City Healthcare Department

Grishin N.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Lozhkin M.V.

City Clinical Oncology Hospital One of the Moscow City Healthcare Department

Troitsky A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Stepanyuk I.V.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center

Bykasov S.A.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center

Moshurov R.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Tumors of peritoneum. Treatment algorithms

Authors:

Sidorov D.V., Grishin N.A., Lozhkin M.V., Troitsky A.A., Stepanyuk I.V., Bykasov S.A., Moshurov R.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(4): 60‑65

Read: 9732 times


To cite this article:

Sidorov DV, Grishin NA, Lozhkin MV, Troitsky AA, Stepanyuk IV, Bykasov SA, Moshurov RI. Tumors of peritoneum. Treatment algorithms. P.A. Herzen Journal of Oncology. 2020;9(4):60‑65. (In Russ.)
https://doi.org/10.17116/onkolog2020904160

Recommended articles:
Fluorescent in situ-hybridization (FISH) in onco­logy. P.A. Herzen Journal of Onco­logy. 2025;(6):88-93

References:

  1. Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511-519.  https://doi.org/10.1080/02656736.2017.1310938
  2. Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-750.  https://doi.org/10.2147/CLEP.S105396
  3. Bouquot M, Dohan A, Gayat E, Barat M, Glehen O, Pocard M, Rousset P, Eveno C. Prediction of resectability in pseudomyxoma peritonei with a new CT score. Ann Surg Oncol. 2018;25(3):694-701.  https://doi.org/10.1245/s10434-017-6275-7
  4. Rizvi SA, Syed W, Shergill R. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018;10(5):49-56.  https://doi.org/10.4240/wjgs.v10.i5.49
  5. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796-803.  https://doi.org/10.1002/jso.24248
  6. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449-2456. https://doi.org/10.1200/jco.2011.39.7166
  7. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of malignant tumours. 8th ed. Wiley Blackwell; 2017.
  8. Llanos MD, Sugarbaker PH. Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. Eur J Surg Oncol. 2017;43(1):138-143.  https://doi.org/10.1016/j.ejso.2016.08.010
  9. Valente K, Blackham AU, Levine E, Russell G, Votanopoulos KI, Stewart JH, Shen P, Geisinger KR, Sirintrapun SJ. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype. Am J Surg Pathol. 2016;40(9):1243-1248. https://doi.org/10.1097/pas.0000000000000696
  10. Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: experience of a peritoneal surface malignancy center. Am Surg. 2015;81(12):1253-1259.
  11. Chirac P, Maillet D, Leprêtre F, Isaac S, Glehen O, Figeac M, Villeneuve L, Péron J, Gibson F, Galateau-Sallé F, Gilly FN, Brevet M. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72-82.  https://doi.org/10.1016/j.humpath.2016.04.015
  12. Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69-79.  https://doi.org/10.1016/j.ejca.2016.06.002
  13. Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative toracoabdominal chemotherapy. Gastroenterol Res Pract. 2012;623417. https://doi.org/10.1155/2012/623417
  14. Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol. 2014;Sep2.pii: S0748-7983(14)01058-0.  https://doi.org/10.1016/j.ejso.2014.08.476
  15. Robella M, Vaira M, Cinquegrana A, Borsano A, DE Simone M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: risk factors for morbidity and postoperative outcome. Minerva Chir. 2018. https://doi.org/10.23736/s0026-4733.18.07649-6
  16. Oemrawsingh A, de Boer NL, Brandt-Kerkhof ARM, Verhoef C, Burger JWA, Madsen EVE. Short-term complications in elderly patients undergoing CRS and HIPEC: A single center’s initial experience. Eur J Surg Oncol. 2018;Nov2.pii:S0748-7983(18)31991-7.  https://doi.org/10.1016/j.ejso.2018.10.545
  17. Suleimanov EA. Intraoperatsionnaya fluorestsentnaya diagnostika i fotodinamicheskaya terapiya bol’nykh s pervichnymi i metastaticheskimi opukholyami bryushiny: Dis. ... d-ra med. nauk. M. 2017. (In Russ.).
  18. Chissov VI, Sidorov DV, Sokolov VV, Filonenko EV, Butenko AV, Grishin NA, Lozhkin MV, Belous TA, Maynovskay OA, Petrov LO. Peritoneal pseudomyxoma: uncommon disease, aggressive treatment. Eur J Surg Oncol. 2010;36(9):911-912. 
  19. Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, Quenet F, Glehen O, Bakrin N, Passot G. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43(11):2178-2183. https://doi.org/10.1016/j.ejso.2017.09.010
  20. Hübner M, Grass F, Teixeira-Farinha H, Pache B, Mathevet P, Demartines N. Pressurized intraperitoneal aerosol chemotherapy — practical aspects. Eur J Surg Oncol. 2017;43(6):1102-1109. https://doi.org/10.1016/j.ejso.2017.03.019
  21. Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;Jan29.pii: S0748-7983(17)30059-8.  https://doi.org/10.1016/j.ejso.2017.01.009
  22. Baumgartner JM, Kwong TG, Ma GL, Messer K, Kelly KJ, Lowy AM. A novel tool for predicting major complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(5):1609-1617. https://doi.org/10.1245/s10434-015-5012-3
  23. Teixeira Farinha H, Grass F, Labgaa I, Pache B, Demartines N, Hübner M. Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy. J Cancer. 2018;9(1):13-20.  https://doi.org/10.7150/jca.21460
  24. Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T. Predictors and outcomes of surgery in peritoneal mesothelioma: an Analysis of 2000 Patients from the National Cancer Database. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-019-08138-5

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.